ストックスクリーナーアプリを入手
3.39
0.59%
-0.02
プレマーケット:
3.36
-0.03
-0.88%
前日終値:
$3.41
開ける：
$3.45
24時間の取引高:
2.37M
Relative Volume:
0.90
時価総額：
$353.88M
収益：
$234.04M
当期純損益:
$-323.92M
株価収益率:
-0.8921
EPS:
-3.8
ネットキャッシュフロー:
$-223.46M
1週間 パフォーマンス:
+10.78%
1か月 パフォーマンス:
+11.88%
6か月 パフォーマンス:
+17.30%
1年 パフォーマンス:
-51.78%
1日の値動き範囲:
$3.3505
$3.495
1週間の範囲:
$3.05
$3.61
52週間の値動き範囲:
$2.30
$7.56
Revance Therapeutics Inc Stock (RVNC) Company Profile
名前
Revance Therapeutics Inc
セクター
電話
(615) 724-7755
住所
1222 DEMONBREUN STREET, NASHVILLE, CA
RVNC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
3.39 | 353.88M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-01-09 | ダウングレード | Goldman | Buy → Neutral |
| 2023-08-16 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-22 | 開始されました | Goldman | Buy |
| 2021-10-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | 繰り返されました | Needham | Buy |
| 2020-08-11 | 再開されました | Mizuho | Buy |
| 2020-03-23 | ダウングレード | Goldman | Buy → Neutral |
| 2019-12-02 | 開始されました | Goldman | Buy |
| 2019-10-30 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-02-15 | 開始されました | Wells Fargo | Market Perform |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
| 2018-11-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2018-09-17 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | 繰り返されました | Mizuho | Buy |
| 2018-03-27 | 開始されました | Needham | Buy |
| 2018-03-05 | 開始されました | Goldman | Buy |
| 2018-01-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2017-12-06 | 開始されました | Guggenheim | Buy |
| 2017-12-06 | 繰り返されました | Mizuho | Buy |
| 2017-11-27 | 開始されました | Barclays | Overweight |
| 2017-11-17 | 開始されました | Mizuho | Buy |
| 2017-08-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Revance Therapeutics Inc (RVNC) 最新ニュース
Kirby McInerney LLP Reminds Revance Therapeutics, Inc. - GlobeNewswire
Kirby McInerney LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Class Action Filing and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - Morningstar
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - Marketscreener.com
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Revance gains as it plans to enter talks with Teoxane on likely superior bid - MSN
Revance to Hold Talks With Teoxane on Takeover Proposal - MarketWatch
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Business Wire
Biotech Co. Revance Faces Suit After Tender Offer Weakens - Law360
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Teoxane Outbids Crown With New Revance Therapeutics Bid - Law360
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Marketscreener.com
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Teoxane makes cash offer to buy Revance Therapeutics By Investing.com - Investing.com Canada
Revance Therapeutics Shares Rise as Teoxane Looks to Upend Crown Deal - MarketWatch
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Teoxane makes cash offer to buy Revance Therapeutics - Investing.com
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash - Yahoo Finance
Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. for $360 million. - Marketscreener.com
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Losses to Contact Firm’s Attorneys Before Feb. 8th Deadline in Securities Fraud Action - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 23.1% in December - MarketBeat
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Given New $3.00 Price Target at Barclays - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc. - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Revance Therapeutics ticks higher as holder says Crown deal undervalues company - MSN
HighTower Advisors LLC Lowers Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Wellington Management Group LLP Invests $2.32 Million in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc.RVNC - Business Wire
Revance Therapeutics' SWOT analysis: tender offer shakes up specialty pharma stock - Investing.com
725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Oddo BHF Asset Management Sas - MarketBeat
Revance receives acquisition offer from Crown Laboratories for $3.10 per share - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - Kilgore News Herald
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
Crown Laboratories Commences Friendly Tender Offer for All Outst - GuruFocus.com
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share - Marketscreener.com
Kirkland Advises Crown Laboratories on Amended Merger Agreement with Revance - Legal Desire News Network
Crown Labs announces merger with Revance Therapeutics - Johnson City Press
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook By Investing.com - Investing.com Nigeria
Revance Therapeutics Inc (RVNC) 財務データ
収益
当期純利益
現金流量
EPS
0.08%
0.05%
大文字化:
|
ボリューム (24 時間):